GO:0007095 mitotic G2 DNA damage checkpoint signaling: Cell Cycle Arrest Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007095 describes the signaling cascade that delays mitotic entry when DNA damage is detected during G2 phase, allowing repair before chromosome segregation.
• The core kinase axis ATM/ATR-CHK1/CHK2-CDC25-WEE1 ultimately inhibits CDK1-cyclin B, holding cells at the G2/M boundary.
• p53 and MAPK signaling modulate cell fate decisions at the G2 checkpoint, determining whether cells arrest, repair, or undergo apoptosis.
• WIP1 (PPM1D) phosphatase is a key negative regulator that turns off the checkpoint and permits mitotic entry after repair.
• Dysregulation of G2 checkpoint signaling is common in cancer, where it contributes to genomic instability and resistance to DNA-damaging therapies.
• CRISPR knockout, point-mutation, and knock-in models are essential to dissect the causal roles of checkpoint genes in disease and therapy response.
Description
The mitotic G2 DNA damage checkpoint signaling pathway (GO:0007095) is a conserved biological process that safeguards genome integrity by preventing cells with damaged DNA from entering mitosis. When DNA lesions are detected during the G2 phase, this signaling cascade delays mitotic entry, providing time for DNA repair before chromosome segregation. This checkpoint is critical for normal development and tissue homeostasis, and its failure leads to genomic instability, a hallmark of cancer. Researchers study this pathway to understand how cells balance proliferation and repair, and to identify therapeutic targets that can sensitize cancer cells to DNA-damaging agents. The pathway integrates signals from ATM/ATR kinases, CHK1/CHK2 effectors, and downstream cell cycle regulators such as CDC25 and WEE1, ultimately controlling the activity of CDK1-cyclin B. Because the checkpoint is frequently altered in tumors, it represents a promising area for precision medicine and drug development.
mitotic G2 DNA damage checkpoint signaling At A Glance
| GO ID | GO:0007095 |
|---|---|
| GO term | mitotic G2 DNA damage checkpoint signaling |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Delays mitotic entry in response to DNA damage during G2 phase to allow repair |
| Key kinases | ATM, ATR, CHK1, CHK2, WEE1, CDK1 |
| Key phosphatases | CDC25A/B/C, WIP1 (PPM1D) |
| Cell cycle phase | G2 phase to M phase transition |
| Disease relevance | Cancer, genomic instability, chemoresistance |
What Is GO:0007095?
GO:0007095 mitotic G2 DNA damage checkpoint signaling is the series of molecular events that detect DNA damage during the G2 phase of the cell cycle and transduce a signal to delay progression into mitosis. This process ensures that DNA lesions are repaired before the cell commits to division, thereby maintaining genomic stability. The checkpoint operates through a kinase cascade that ultimately inhibits the CDK1-cyclin B complex, preventing entry into mitosis until damage is resolved.
Why Is mitotic G2 DNA damage checkpoint signaling Important in Cell Biology?
The mitotic G2 DNA damage checkpoint is essential for maintaining genomic integrity by preventing cells from entering mitosis with unrepaired DNA. Its dysfunction is a major contributor to tumorigenesis and influences the efficacy of DNA-damaging chemotherapies and radiation. Understanding this pathway provides insights into cancer biology, aging, and potential therapeutic strategies that target checkpoint kinases.
• Prevents genomic instability by delaying mitosis until DNA damage is repaired.
• Frequently dysregulated in cancer, contributing to tumor progression and therapy resistance.
• Modulates cell fate decisions between arrest, apoptosis, and senescence through p53 and MAPK signaling.
• Regulated by phosphatases such as WIP1, which turn off the checkpoint to allow mitotic entry.
• Targeted by investigational drugs (e.g., CHK1/CHK2 inhibitors) to sensitize tumors to DNA damage.
• Involved in normal development and tissue homeostasis by protecting stem cells from DNA damage.
• Cross-talks with other pathways such as PLK1-NOTCH1 signaling during DNA damage and mitotic progression.
• Oncogenic fusions (e.g., ETS fusions) can induce DNA damage responses that intersect with G2 checkpoint control.
• Plays a role in the cellular response to agricultural chemicals and environmental toxicants.
• Serves as a model for studying signal transduction and cell cycle checkpoints.
What Happens During mitotic G2 DNA damage checkpoint signaling?
DNA Damage Detection and Sensor Activation
In simple terms: When DNA is damaged, sensor proteins recognize the problem and start a signaling chain.
During G2 phase, DNA lesions such as double-strand breaks or replication stress are detected by sensor complexes that recruit and activate the ATM and ATR kinases. ATM is primarily activated by double-strand breaks, while ATR responds to single-stranded DNA and replication protein A-coated lesions. These kinases initiate a phosphorylation cascade that amplifies the damage signal.
Signal Transduction via CHK1 and CHK2
In simple terms: The sensor kinases activate effector kinases that spread the alarm.
ATM phosphorylates and activates CHK2, while ATR activates CHK1. These effector kinases phosphorylate downstream targets, including the CDC25 phosphatases and p53, to enforce cell cycle arrest. The balance between CHK1 and CHK2 activity influences the duration and strength of the checkpoint response.
Inhibition of CDK1-Cyclin B and G2/M Arrest
In simple terms: The signal ultimately blocks the engine that drives cells into mitosis.
CHK1 and CHK2 phosphorylate CDC25 family phosphatases, leading to their inhibition or degradation, which prevents the activating dephosphorylation of CDK1. Simultaneously, WEE1 kinase phosphorylates CDK1 to keep it inactive. This dual regulation ensures that CDK1-cyclin B remains inhibited, causing a G2 arrest.
Cell Fate Decisions: Repair, Apoptosis, or Senescence
In simple terms: The cell decides whether to fix the damage, die, or stop dividing permanently.
The G2 checkpoint is not a simple on/off switch; it integrates signals from p53 and MAPK pathways to determine cell fate. Pulsatile MAPK signaling modulates p53 activity, influencing whether cells undergo prolonged arrest, apoptosis, or senescence. If repair is successful, the checkpoint is turned off and mitosis resumes; if damage is irreparable, apoptosis or senescence is triggered.
Checkpoint Silencing and Mitotic Entry
In simple terms: Once damage is fixed, the brake is released and the cell divides.
Checkpoint silencing requires the inactivation of ATM/ATR and the reversal of inhibitory phosphorylations. WIP1 (PPM1D) phosphatase dephosphorylates key checkpoint proteins, including ATM, CHK1, and p53, to terminate the signal. Mutations in WIP1 can suppress the DNA damage-triggered bypass of the mitotic timer, leading to premature mitosis. PLK1 also contributes to checkpoint recovery and mitotic progression by targeting NOTCH1 and other substrates.
Key Genes Involved in GO:0007095 mitotic G2 DNA damage checkpoint signaling
The following genes and proteins are central to the mitotic G2 DNA damage checkpoint signaling pathway, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATM | Sensor kinase activated by DNA double-strand breaks; initiates checkpoint signaling | Mutations cause ataxia-telangiectasia; target for radiosensitization |
| ATR | Sensor kinase responding to single-stranded DNA and replication stress | Inhibitors are in clinical trials for cancer therapy |
| CHK1 | Effector kinase phosphorylated by ATR; inhibits CDC25 and promotes arrest | Target for chemosensitization; regulates replication fork stability |
| CHK2 | Effector kinase phosphorylated by ATM; phosphorylates p53 and CDC25 | Mutations linked to cancer predisposition; biomarker for DNA damage response |
| CDC25A | Phosphatase that activates CDK1; inhibited by CHK1/CHK2 | Overexpressed in cancers; target for degradation-inducing drugs |
| CDC25B | Phosphatase that activates CDK1; regulated by checkpoint kinases | Involved in mitotic entry; potential oncogene |
| CDC25C | Phosphatase that dephosphorylates CDK1; inhibited by CHK1/CHK2 | Key regulator of G2/M transition; altered in tumors |
| WEE1 | Kinase that phosphorylates and inhibits CDK1 | Target for cancer therapy; inhibitor adavosertib in trials |
| CDK1 | Cyclin-dependent kinase that drives mitosis; inhibited by checkpoint | Central effector; target for cell cycle inhibitors |
| CCNB1 | Cyclin B1, regulatory subunit of CDK1 | Overexpressed in many cancers; marker of proliferation |
| TP53 | Tumor suppressor; phosphorylated by ATM/CHK2; induces p21 and apoptosis | Most commonly mutated gene in cancer; determines cell fate |
| PPM1D | WIP1 phosphatase; dephosphorylates ATM, CHK1, p53 to silence checkpoint | Mutations suppress mitotic timer bypass; amplified in cancers |
| PLK1 | Polo-like kinase 1; regulates checkpoint recovery and mitosis | Targets NOTCH1 during DNA damage; inhibitor in trials |
| NOTCH1 | Substrate of PLK1; involved in DNA damage and mitotic progression | Cross-talk with checkpoint; role in cancer and development |
| MAPK1 | ERK2; modulates p53 activity and cell fate at G2 checkpoint | Pulsatile signaling controls arrest vs apoptosis |
| MAPK3 | ERK1; participates in MAPK signaling to p53 | Influences checkpoint decision-making |
| BORA | Activates PLK1 during mitosis; phosphorylated by cAMP-PKA | Links cAMP-PKA signaling to mitotic entry |
| ETS fusions | Oncogenic fusions that induce DNA damage and proinflammatory responses | Model for studying DNA damage in cancer; potential therapeutic targets |
How Is mitotic G2 DNA damage checkpoint signaling Regulated?
The mitotic G2 DNA damage checkpoint is tightly regulated by phosphorylation and dephosphorylation events. ATM and ATR kinases initiate the signal, while WIP1 phosphatase acts as a negative regulator by dephosphorylating ATM, CHK1, and p53 to turn off the checkpoint. PLK1 kinase promotes checkpoint recovery and mitotic entry by targeting NOTCH1 and other substrates. Additionally, cAMP-PKA signaling phosphorylates Bora to initiate mitosis, providing a link between metabolic signaling and mitotic entry. Pulsatile MAPK signaling modulates p53 activity to control cell fate decisions at the G2 checkpoint.
mitotic G2 DNA damage checkpoint signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Li-Fraumeni syndrome, many cancers; impaired G2 checkpoint | TP53 knockout or point-mutation cell lines (e.g., HCT116 p53-/-) |
| ATM | Ataxia-telangiectasia; radiosensitivity; cancer predisposition | ATM knockout iPSCs or HeLa cells; patient-derived fibroblasts |
| CHK2 | Cancer predisposition; defective DNA damage response | CHK2 knockout HCT116 or MCF7 cells |
| PPM1D | Amplified in cancers; suppresses mitotic timer bypass | WIP1 mutant knock-in cell lines; overexpression models |
| ETS fusions | Oncogenic fusions in prostate cancer; induce DNA damage | Knock-in of ETS fusion in prostate epithelial cells |
Cancer and Genomic Instability
Dysregulation of the mitotic G2 DNA damage checkpoint is a hallmark of cancer, leading to genomic instability and tumor progression. Mutations in TP53, ATM, and CHK2 impair checkpoint function, allowing cells with damaged DNA to enter mitosis and accumulate mutations. Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs, further linking checkpoint dysfunction to cancer. Targeting checkpoint kinases such as CHK1, WEE1, and PLK1 is a promising therapeutic strategy to sensitize tumors to DNA-damaging agents.
Chemoresistance and Therapy Response
The G2 checkpoint contributes to chemoresistance by allowing cancer cells to repair DNA damage induced by chemotherapy or radiation. Inhibitors of CHK1, CHK2, and WEE1 are being developed to abrogate the checkpoint and enhance the efficacy of DNA-damaging therapies. WIP1 mutations that suppress the DNA damage-triggered bypass of the mitotic timer can also influence therapy response.
Environmental Toxicity and Cellular Stress
Exposure to environmental toxicants such as the agricultural chemical thiabendazole can activate DNA damage responses and modulate checkpoint signaling, as revealed by network toxicology and molecular docking studies. This highlights the broader relevance of the G2 checkpoint in toxicology and public health.
From mitotic G2 DNA damage checkpoint signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate G2 checkpoint arrest? | CRISPR knockout of gene X in HeLa or U2OS cells followed by DNA damage and cell cycle analysis |
| Does a specific point mutation in TP53 affect cell fate at G2? | Point-mutation knock-in of TP53 in HCT116 or RPE1 cells |
| Does WIP1 mutation suppress mitotic timer bypass? | WIP1 mutant knock-in or knockout in cancer cell lines |
| Does overexpression of CDC25A override checkpoint arrest? | Doxycycline-inducible overexpression of CDC25A in p53-deficient cells |
| Does PLK1-mediated NOTCH1 phosphorylation affect mitotic progression? | Tagged knock-in of NOTCH1 with phospho-mutant or phospho-mimetic alleles |
| Does cAMP-PKA signaling regulate Bora to initiate mitosis? | Knock-in of Bora phospho-mutants in HeLa cells |
How to Study the mitotic G2 DNA damage checkpoint signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Cell cycle distribution and mitotic index | Quantify G2 arrest after DNA damage |
| Western blotting | Phosphorylation status of checkpoint proteins | Monitor ATM/CHK1/CHK2 activation |
| Live-cell imaging | Real-time dynamics of CDK1-cyclin B and cell fate | Study pulsatile MAPK signaling and p53 decisions |
| CRISPR knockout screens | Identification of genes required for checkpoint | Discover novel regulators |
| RNA-seq | Transcriptional changes upon checkpoint activation | Analyze p53 target genes and pathway crosstalk |
| Proteomics | Protein-protein interactions and post-translational modifications | Map checkpoint signaling complexes |
| Molecular docking | Binding affinity of chemicals to checkpoint proteins | Toxicology and drug discovery |
| Comet assay | DNA damage levels | Assess repair efficiency after checkpoint release |
Cell Cycle Analysis by Flow Cytometry
Flow cytometry using DNA dyes (e.g., propidium iodide) and phospho-histone H3 staining is standard to measure G2/M arrest after DNA damage. This method quantifies the percentage of cells in G2 phase and mitotic cells, providing a readout of checkpoint activity.
Western Blotting for Checkpoint Phosphorylation
Western blotting with phospho-specific antibodies against ATM (S1981), CHK1 (S345), CHK2 (T68), and p53 (S15) is used to monitor checkpoint activation and silencing. This technique reveals the kinetics of kinase activation and the effects of genetic perturbations.
Live-Cell Imaging of Checkpoint Dynamics
Live-cell imaging with fluorescently tagged proteins (e.g., GFP-CDK1, mCherry-cyclin B) allows real-time visualization of checkpoint arrest and recovery in single cells. This approach captures pulsatile signaling dynamics and cell fate decisions.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify novel regulators of the G2 checkpoint. Combined with bioinformatics, these screens reveal pathways that modulate checkpoint sensitivity to DNA damage.
How CRISPR Can Be Used to Study GO:0007095 mitotic G2 DNA damage checkpoint signaling
Knockout
CRISPR knockout of checkpoint genes such as ATM, CHK1, CHK2, or WEE1 is used to abrogate G2 arrest and study downstream effects on DNA repair and cell survival. Knockout cell lines are valuable for drug sensitivity testing and identifying synthetic lethal interactions.
Point Mutation
Point mutations in TP53, PPM1D, or CDC25 genes can be introduced via CRISPR to model clinical mutations and dissect their impact on checkpoint function and cell fate. These models help determine whether specific mutations alter checkpoint stringency or therapy response.
Knock-in
Tagged knock-in of checkpoint proteins (e.g., GFP-CDK1, HA-CHK1) allows real-time imaging and biochemical analysis of protein dynamics during checkpoint activation and recovery. Knock-in of phospho-mutant alleles (e.g., NOTCH1) can reveal phosphorylation-dependent functions.
Overexpression
Overexpression of checkpoint regulators such as CDC25A, WIP1, or PLK1 can override checkpoint arrest and promote premature mitosis, modeling oncogenic events. Inducible overexpression systems provide temporal control to study checkpoint silencing.
How EDITGENE Supports mitotic G2 DNA damage checkpoint signaling Research
Researchers studying mitotic G2 DNA damage checkpoint signaling-related genes often need to determine whether a candidate gene is causally involved in checkpoint control, DNA repair, or cell fate decisions. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for mitotic G2 DNA damage checkpoint signaling research.
Frequently Asked Questions About mitotic G2 DNA damage checkpoint signaling
What is GO:0007095 mitotic G2 DNA damage checkpoint signaling?
GO:0007095 is a biological process that delays entry into mitosis when DNA damage is detected during G2 phase, allowing time for DNA repair.
What genes are involved in the mitotic G2 DNA damage checkpoint?
Key genes include ATM, ATR, CHK1, CHK2, CDC25A/B/C, WEE1, CDK1, CCNB1, TP53, PPM1D, PLK1, and NOTCH1.
How does the G2 DNA damage checkpoint work?
DNA damage activates ATM/ATR kinases, which phosphorylate CHK1/CHK2; these inhibit CDC25 phosphatases and activate WEE1, leading to CDK1 inhibition and G2 arrest.
Why is the G2 checkpoint important in cancer?
Dysregulation of the G2 checkpoint allows cells with damaged DNA to divide, causing genomic instability and contributing to cancer progression and therapy resistance.
What is the role of p53 in the G2 checkpoint?
p53 is phosphorylated by ATM/CHK2 and induces p21, causing cell cycle arrest or apoptosis; pulsatile MAPK signaling modulates p53 activity to control cell fate.
How is the G2 checkpoint turned off?
WIP1 (PPM1D) phosphatase dephosphorylates ATM, CHK1, and p53 to silence the checkpoint, while PLK1 promotes recovery and mitotic entry.
What experimental models are used to study the G2 checkpoint?
Common models include CRISPR knockout cell lines, point-mutation knock-ins, tagged knock-ins for imaging, and overexpression systems, combined with flow cytometry and western blotting.
What drugs target the G2 checkpoint?
Inhibitors of CHK1, CHK2, WEE1, and PLK1 are in preclinical and clinical development to sensitize cancer cells to DNA-damaging therapies.
How does WIP1 mutation affect the mitotic timer?
WIP1 mutations suppress DNA damage-triggered bypass of the mitotic timer, leading to premature mitosis and genomic instability.
What is the link between ETS fusions and the G2 checkpoint?
Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs, which can activate checkpoint signaling.
Conclusion
The mitotic G2 DNA damage checkpoint signaling pathway (GO:0007095) is a critical guardian of genomic integrity, coordinating DNA repair with cell cycle progression. Its dysregulation is intimately linked to cancer and therapy resistance, making it a prime target for drug development. CRISPR-based models are indispensable for dissecting the causal roles of checkpoint genes and for identifying new therapeutic strategies.
References
- 1. Glaviano A et al.. 2025. Cell cycle dysregulation in cancer.. Pharmacol Rev 77(2):100030 PMID: 40148026
- 2. He J et al.. 2024. Network toxicological and molecular docking to investigate the mechanisms of toxicity of agricultural chemical Thiabendazole.. Chemosphere 363:142711 PMID: 38964723
- 3. Sobajima T et al.. 2025. WIP1 mutations suppress DNA damage triggered bypass of the mitotic timer.. EMBO J 44(15):4378-4405 PMID: 40551011
- 4. De S et al.. 2020. Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage.. Cell Rep 30(7):2083-2093.e5 PMID: 32075732
- 5. Zhu M et al.. 2025. The cAMP-PKA signaling initiates mitosis by phosphorylating Bora.. Nat Commun 16(1):7898 PMID: 40849432
- 6. Calonge TM et al.. 2008. Turning off the G2 DNA damage checkpoint.. DNA Repair (Amst) 7(2):136-40 PMID: 17851138
- 7. De Blasio C et al.. 2019. PLK1 targets NOTCH1 during DNA damage and mitotic progression.. J Biol Chem 294(47):17941-17950 PMID: 31597699
- 8. Ruzanov P et al.. 2024. Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles.. J Clin Invest 134(9) PMID: 38530366
